Celyad is about to kick the THINK trial in the USA, after the U.S. FDA authorized its initiation. THINK evaluates NKR-2 CAR-T cells in seven indications, five solid cancers and two hematological malignancies.
“The FDA approval for the THINK trial is an important milestone allowing us to initiate the THINK clinical trial in the USA. We are now looking forward to enrolling the first patients in both solid and hematological arms of the study in the U.S.,” said Christian Homsy, CEO of Celyad.
Jean-Pierre Latere, Chief Operating Officer at Celyad, said the company will focus to the recruitment and follow-up of new patients in next months for each dose-level cohort, and also to the opening of new clinical sites across EU and the U.S..
Ceylad in January activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient at Cliniques Universitaires Saint-Luc (UCL). The THINK trial is a world first, evaluating CAR-T NKR-2 cells in both hematological and solid tumors